GlassScriptPhysician profile
Kelly A Boardman
NPI 1821492067
$3,367.43
in general payments reported to CMS, 2019-2025
27 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $608 · 2023: $1,041 · 2024: $690 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,501.78 | 2021-2025 | |
| Novo Nordisk INC | $499.53 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $322.39 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $179.61 | 2021-2025 | Bexsero, Pediarix, Rotarix |
| Lilly USA, LLC | $142.45 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $131.22 | 2021-2025 | |
| Cranial Technologies, INC | $61.63 | 2023-2024 | Doc Band |
| Astellas Pharma US INC | $60.43 | 2023-2024 | Veozah, Myrbetriq |
| Vanda Pharmaceuticals INC. | $51.33 | 2022 | |
| Amgen INC. | $43.84 | 2023-2025 | Otezla, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $40.51 | 2022-2024 | Eliquis |
| Cleerly, INC. | $39.76 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Biohaven Pharmaceutical Holding Company LTD. | $29.09 | 2022 | |
| Merck Sharp & Dohme LLC | $28.48 | 2024 | M-M-R II, Capvaxive, Gardasil |
| Tms Neurohealth Centers INC. | $24.81 | 2025 | Tms Neurohealth Centers INC. |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $24.75 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $22.86 | 2021 | |
| Axsome Therapeutics, INC. | $18.82 | 2024 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $18.25 | 2024 | Crysvita |
| Sanofi Pasteur INC. | $18.02 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.63 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $15.89 | 2025 | Zoryve |
| Novavax INC | $15.49 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Hikma Pharmaceuticals USA | $15.41 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.41 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.65 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $14.39 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Boardman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.